BCM
TTOO

Bayesian Capital Management’s T2 Biosystems, Inc TTOO Stock Holding History

Bayesian Capital Management’s Portfolio TTOO Stock Details TTOO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2
Closed -$86K – 829
2018
Q3 		$86K Hold
2
– – 0.01% 595
2018
Q2 		$82K Buy
+2
New +$75.9K 0.02% 561

Other funds holding TTOO

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayesian Capital Management's TTOO Position: Q4 2018 in Review

Bayesian Capital Management sold out of T2 Biosystems, Inc (TTOO) in Q4 2018, closing a stake of 2 shares — an estimated $86K sold.

Bayesian Capital Management first reported a position in TTOO in Q2 2018 and held it in 2 quarters. The position peaked at $86K in Q3 2018. 84 funds tracked by Wall St. Rank hold TTOO as of Q4 2018.

  • Bayesian Capital Management reported no remaining T2 Biosystems, Inc position as of Q4 2018 after selling out during the quarter.
  • Bayesian Capital Management sold 2 T2 Biosystems, Inc shares in Q4 2018, an estimated $86K.
  • Bayesian Capital Management first reported a position in T2 Biosystems, Inc in Q2 2018 and held it in 2 quarters.
  • Bayesian Capital Management's T2 Biosystems, Inc position peaked at $86K in Q3 2018.
  • 84 funds tracked by Wall St. Rank held T2 Biosystems, Inc as of Q4 2018.

Based on Bayesian Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.